Successes and Challenges of PARP Inhibitors in Cancer Therapy

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 5; p. 222
Main Authors Ricks, Tiffany K., Chiu, Haw-Jyh, Ison, Gwynn, Kim, Geoffrey, McKee, Amy E., Kluetz, Paul, Pazdur, Richard
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.10.2015
Subjects
BRCA1
BRCA2
Cancer
Drug Resistance
Homologous Recombination
Oncology
PARP inhibitor
cancer
BRCA1
drug resistance
homologous recombination
BRCA2
PARP inhibitor
Online AccessGet full text

Cover

Author Chiu, Haw-Jyh
Ison, Gwynn
Kim, Geoffrey
McKee, Amy E.
Kluetz, Paul
Pazdur, Richard
Ricks, Tiffany K.
AuthorAffiliation 1 Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA
AuthorAffiliation_xml – name: 1 Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA
Author_xml – sequence: 1
  givenname: Tiffany K.
  surname: Ricks
  fullname: Ricks, Tiffany K.
– sequence: 2
  givenname: Haw-Jyh
  surname: Chiu
  fullname: Chiu, Haw-Jyh
– sequence: 3
  givenname: Gwynn
  surname: Ison
  fullname: Ison, Gwynn
– sequence: 4
  givenname: Geoffrey
  surname: Kim
  fullname: Kim, Geoffrey
– sequence: 5
  givenname: Amy E.
  surname: McKee
  fullname: McKee, Amy E.
– sequence: 6
  givenname: Paul
  surname: Kluetz
  fullname: Kluetz, Paul
– sequence: 7
  givenname: Richard
  surname: Pazdur
  fullname: Pazdur, Richard
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26528434$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtrGzEUhUVJadI06-7KLLuxI-neGc8sWgimD0OgoU0gO6GRrmyFseRK40D-feU4CUmg2uh1zneEznt2EGIgxj4KPgVou1MXg5lKLuop51LKN-xISsBJh3B98Gx9yE5yvuFlNDUXHN6xQ9nUskXAI_blz9YYyplypYOt5is9DBSWZRtddXH2-6JahJXv_RhTrnyo5joYStXlipLe3H1gb50eMp08zMfs6vu3y_nPyfmvH4v52fnEYN2NE3RWCgLULSfiIGRfHtBoNE3bN86g6xANaMulM5bXbW86cEC8s9hp3Qo4Zos910Z9ozbJr3W6U1F7dX8Q01LpNHozkMIeZv3MGeBSIC8MjjMrGkEWpbOIhfV1z9ps-zVZQ2FMengBfXkT_Eot463ChiMIKIDPD4AU_24pj2rts6Fh0IHiNisxg9JH3ciuSD89z3oKefz_Iqj3ApNizomcMn7Uo4-7aD8owdWuarWrWu2qVvdVF9_pK98j-n-Of95EqpU
CitedBy_id crossref_primary_10_1021_acsomega_8b00896
crossref_primary_10_1021_acs_jmedchem_8b01407
crossref_primary_10_1038_onc_2016_392
crossref_primary_10_3390_biomedicines9050565
crossref_primary_10_1128_MMBR_00038_18
crossref_primary_10_1136_esmoopen_2017_000172
crossref_primary_10_1016_j_ccell_2019_05_001
crossref_primary_10_30683_1927_7229_2023_12_09
crossref_primary_10_1158_1078_0432_CCR_17_0143
crossref_primary_10_1080_14656566_2021_1952983
crossref_primary_10_1134_S0026893316040038
crossref_primary_10_3389_fphar_2022_842316
crossref_primary_10_3389_fgene_2018_00188
crossref_primary_10_1242_jcs_203513
crossref_primary_10_1002_med_21442
crossref_primary_10_1038_s41698_022_00319_y
crossref_primary_10_1080_13543784_2024_2391828
crossref_primary_10_3892_etm_2021_10367
crossref_primary_10_51847_asgta1QMY9
crossref_primary_10_3390_molecules21060772
crossref_primary_10_4103_jcsr_jcsr_217_22
crossref_primary_10_1007_s00706_023_03069_0
crossref_primary_10_3390_ijms23094806
crossref_primary_10_3390_ijms18010023
crossref_primary_10_1208_s12249_019_1468_y
crossref_primary_10_1007_s12672_025_02048_7
crossref_primary_10_1007_s40265_016_0688_7
crossref_primary_10_3802_jgo_2019_30_e26
crossref_primary_10_1016_j_clgc_2017_07_005
crossref_primary_10_1007_s40944_017_0155_8
crossref_primary_10_1182_bloodadvances_2021004638
crossref_primary_10_3389_fgene_2019_00503
crossref_primary_10_1021_acs_jmedchem_8b00576
crossref_primary_10_1016_j_bioorg_2020_104075
crossref_primary_10_3390_cancers13133136
crossref_primary_10_1007_s13669_018_0233_7
crossref_primary_10_1158_1541_7786_MCR_18_0523
crossref_primary_10_1016_j_jchromb_2019_121925
crossref_primary_10_3390_molecules24244498
crossref_primary_10_1177_1010428317727479
crossref_primary_10_1158_0008_5472_CAN_20_0530
crossref_primary_10_1021_acs_biochem_7b00670
crossref_primary_10_1016_j_path_2016_01_003
crossref_primary_10_3892_ol_2019_10882
crossref_primary_10_1146_annurev_pharmtox_010716_105001
crossref_primary_10_3389_fimmu_2021_737311
crossref_primary_10_1016_j_jtho_2021_04_001
crossref_primary_10_3389_fonc_2023_1295579
crossref_primary_10_3390_ncrna7040060
crossref_primary_10_3390_cells9010041
Cites_doi 10.1093/nar/gkl840
10.1158/2159-8290.CD-12-0514
10.1136/jmedgenet-2013-101642
10.1038/nature06633
10.1093/nar/gkq1241
10.1016/S0140-6736(10)60893-8
10.1056/NEJMoa0900212
10.1038/nature03445
10.1002/path.4140
10.1158/1078-0432.CCR-08-1223
10.1074/jbc.274.29.20521
10.1158/1078-0432.CCR-13-0225
10.1186/bcr3670
10.3389/fonc.2013.00228
10.1158/2159-8290.CD-12-0049
10.1038/nature03443
10.1073/pnas.1013715108
10.1038/onc.2013.352
10.1158/0008-5472.CAN-06-0140
10.1158/1078-0432.CCR-08-0214
10.1371/journal.pone.0026152
10.1074/jbc.M006520200
10.1038/nature06548
10.1158/1078-0432.CCR-14-2572
10.1016/j.molonc.2011.07.001
10.1038/nrm3376
10.1016/j.coph.2008.06.016
10.1158/1535-7163.MCT-13-0803
10.1158/1078-0432.CCR-13-1391
10.1038/283593a0
10.1016/S0140-6736(10)60892-6
10.1038/nrm1963
10.1016/j.mam.2013.01.006
10.1074/jbc.M311606200
10.1016/j.cub.2005.01.029
10.1200/JCO.2008.19.7681
10.1158/1078-0432.CCR-15-0887
10.1158/0008-5472.CAN-12-2753
10.1038/nrc2812
10.1158/1541-7786.MCR-15-0191-T
10.1074/jbc.273.10.5858
10.1056/NEJMra0809889
ContentType Journal Article
Copyright Copyright © 2015 Ricks, Chiu, Ison, Kim, McKee, Kluetz and Pazdur. 2015 Ricks, Chiu, Ison, Kim, McKee, Kluetz and Pazdur
Copyright_xml – notice: Copyright © 2015 Ricks, Chiu, Ison, Kim, McKee, Kluetz and Pazdur. 2015 Ricks, Chiu, Ison, Kim, McKee, Kluetz and Pazdur
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2015.00222
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
EndPage 222
ExternalDocumentID oai_doaj_org_article_4b37b7fc302140e09047d161ed42fd44
PMC4604313
26528434
10_3389_fonc_2015_00222
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c459t-4fd21e34a80ee0312b2656a4c68b6fc4f944c3ad02fcd058bc93f3e09d49aa813
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:20:55 EDT 2025
Thu Aug 21 18:24:02 EDT 2025
Fri Jul 11 03:21:03 EDT 2025
Thu Apr 03 07:05:54 EDT 2025
Tue Jul 01 03:12:55 EDT 2025
Thu Apr 24 23:01:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords cancer
BRCA1
drug resistance
homologous recombination
BRCA2
PARP inhibitor
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-4fd21e34a80ee0312b2656a4c68b6fc4f944c3ad02fcd058bc93f3e09d49aa813
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Christina Annunziata, National Cancer Institute, USA
Reviewed by: Lawrence Panasci, Jewish General Hospital, Canada; Shiv K. Gupta, Mayo Clinic, USA; Joyce Liu, Dana-Farber Cancer Institute, USA
Specialty section: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
OpenAccessLink https://doaj.org/article/4b37b7fc302140e09047d161ed42fd44
PMID 26528434
PQID 1730025629
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_4b37b7fc302140e09047d161ed42fd44
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4604313
proquest_miscellaneous_1730025629
pubmed_primary_26528434
crossref_citationtrail_10_3389_fonc_2015_00222
crossref_primary_10_3389_fonc_2015_00222
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-10-14
PublicationDateYYYYMMDD 2015-10-14
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-14
  day: 14
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2015
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Galande (B15) 1999; 274
Li (B16) 2004; 279
McCabe (B11) 2006; 66
Edwards (B31) 2008; 451
McNeish (B41) 2015; 33
Helleday (B14) 2011; 5
Patel (B12) 2011; 108
Durkacz (B10) 1980; 283
Bryant (B3) 2005; 434
Murai (B19) 2012; 72
Kummar (B24) 2009; 27
Kim (B5) 2015; 21
Meyer (B40) 2014; 51
Bouwman (B29) 2014; 20
Tutt (B27) 2010; 376
Strom (B21) 2011; 39
Hopkins (B22) 2015
Lord (B30) 2008; 8
Sakai (B32) 2008; 451
Michels (B43) 2014; 33
Rogakou (B37) 1998; 273
D’Andrea (B39) 2010; 362
Gibson (B1) 2012; 13
Rouleau (B7) 2010; 10
Farmer (B4) 2005; 434
Kinders (B23) 2008; 14
Shen (B8) 2013; 19
Lowndes (B36) 2005; 15
Wang (B18) 2006; 34
Curtin (B6) 2013; 34
De Lorenzo (B13) 2013; 3
Smith (B38) 2015; 21
Ji (B25) 2011; 6
Jaspers (B35) 2013; 3
Plummer (B9) 2008; 14
Murai (B20) 2014; 13
Audeh (B26) 2010; 376
Barber (B33) 2013; 229
Pleschke (B17) 2000; 275
Fojo (B34) 2013; 3
Watkins (B42) 2014; 16
Fong (B28) 2009; 361
Schreiber (B2) 2006; 7
21300883 - Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
14734561 - J Biol Chem. 2004 Apr 2;279(14 ):13659-67
24037533 - Oncogene. 2014 Jul 24;33(30):3894-907
9488723 - J Biol Chem. 1998 Mar 6;273(10):5858-68
18264087 - Nature. 2008 Feb 28;451(7182):1116-20
26217019 - Mol Cancer Res. 2015 Nov;13(11):1465-77
23118055 - Cancer Res. 2012 Nov 1;72 (21):5588-99
11016934 - J Biol Chem. 2000 Dec 29;275(52):40974-80
25500058 - Clin Cancer Res. 2015 Feb 15;21(4):819-32
20484397 - N Engl J Med. 2010 May 20;362(20):1909-19
25093514 - Breast Cancer Res. 2014 Jun 03;16(3):211
17088286 - Nucleic Acids Res. 2006;34(21):6170-82
15694301 - Curr Biol. 2005 Feb 8;15(3):R99-R102
15829966 - Nature. 2005 Apr 14;434(7035):913-7
19047122 - Clin Cancer Res. 2008 Dec 1;14 (23 ):7917-23
21183466 - Nucleic Acids Res. 2011 Apr;39(8):3166-75
24259538 - J Med Genet. 2014 Feb;51(2):71-5
21821475 - Mol Oncol. 2011 Aug;5(4):387-93
16829982 - Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
23319766 - Cancer Discov. 2013 Jan;3(1):20-3
10400681 - J Biol Chem. 1999 Jul 16;274(29):20521-8
24270682 - Clin Cancer Res. 2014 Feb 1;20(3):540-7
23370117 - Mol Aspects Med. 2013 Dec;34(6):1217-56
19553641 - N Engl J Med. 2009 Jul 9;361(2):123-34
23881923 - Clin Cancer Res. 2013 Sep 15;19(18):5003-15
23165508 - J Pathol. 2013 Feb;229(3):422-9
20609468 - Lancet. 2010 Jul 24;376(9737):245-51
6243744 - Nature. 1980 Feb 7;283(5747):593-6
15829967 - Nature. 2005 Apr 14;434(7035):917-21
16912188 - Cancer Res. 2006 Aug 15;66(16):8109-15
18980982 - Clin Cancer Res. 2008 Nov 1;14(21):6877-85
20609467 - Lancet. 2010 Jul 24;376(9737):235-44
20200537 - Nat Rev Cancer. 2010 Apr;10 (4):293-301
18644251 - Curr Opin Pharmacol. 2008 Aug;8(4):363-9
19364967 - J Clin Oncol. 2009 Jun 1;27(16):2705-11
24062981 - Front Oncol. 2013 Sep 11;3:228
23103855 - Cancer Discov. 2013 Jan;3(1):68-81
26187614 - Clin Cancer Res. 2015 Oct 1;21(19):4257-61
22713970 - Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24
24356813 - Mol Cancer Ther. 2014 Feb;13(2):433-43
18264088 - Nature. 2008 Feb 28;451(7182):1111-5
22028822 - PLoS One. 2011;6(10):e26152
References_xml – volume: 34
  start-page: 6170
  year: 2006
  ident: B18
  article-title: PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkl840
– volume: 3
  start-page: 20
  year: 2013
  ident: B34
  article-title: Mechanisms of resistance to PARP inhibitors – three and counting
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0514
– volume: 51
  start-page: 71
  year: 2014
  ident: B40
  article-title: Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling
  publication-title: J Med Genet
  doi: 10.1136/jmedgenet-2013-101642
– volume: 451
  start-page: 1116
  year: 2008
  ident: B32
  article-title: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
  publication-title: Nature
  doi: 10.1038/nature06633
– volume: 39
  start-page: 3166
  year: 2011
  ident: B21
  article-title: Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkq1241
– volume: 33
  start-page: 5508
  year: 2015
  ident: B41
  article-title: Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis
  publication-title: ASCO Meeting Abstracts
– volume: 376
  start-page: 245
  year: 2010
  ident: B26
  article-title: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60893-8
– volume: 361
  start-page: 123
  year: 2009
  ident: B28
  article-title: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0900212
– volume: 434
  start-page: 917
  year: 2005
  ident: B4
  article-title: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
  publication-title: Nature
  doi: 10.1038/nature03445
– volume: 229
  start-page: 422
  year: 2013
  ident: B33
  article-title: Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
  publication-title: J Pathol
  doi: 10.1002/path.4140
– volume: 14
  start-page: 7917
  year: 2008
  ident: B9
  article-title: Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1223
– volume: 274
  start-page: 20521
  year: 1999
  ident: B15
  article-title: Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences
  publication-title: J Biol Chem
  doi: 10.1074/jbc.274.29.20521
– volume: 20
  start-page: 540
  year: 2014
  ident: B29
  article-title: Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0225
– volume: 16
  start-page: 211
  year: 2014
  ident: B42
  article-title: Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3670
– volume: 3
  start-page: 228
  year: 2013
  ident: B13
  article-title: The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells
  publication-title: Front Oncol
  doi: 10.3389/fonc.2013.00228
– volume: 3
  start-page: 68
  year: 2013
  ident: B35
  article-title: Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0049
– volume: 434
  start-page: 913
  year: 2005
  ident: B3
  article-title: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
  publication-title: Nature
  doi: 10.1038/nature03443
– volume: 108
  start-page: 3406
  year: 2011
  ident: B12
  article-title: Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1013715108
– volume: 33
  start-page: 3894
  year: 2014
  ident: B43
  article-title: Predictive biomarkers for cancer therapy with PARP inhibitors
  publication-title: Oncogene
  doi: 10.1038/onc.2013.352
– volume: 66
  start-page: 8109
  year: 2006
  ident: B11
  article-title: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0140
– volume: 14
  start-page: 6877
  year: 2008
  ident: B23
  article-title: Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-0214
– volume: 6
  start-page: e26152
  year: 2011
  ident: B25
  article-title: Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0026152
– volume: 275
  start-page: 40974
  year: 2000
  ident: B17
  article-title: Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M006520200
– volume: 451
  start-page: 1111
  year: 2008
  ident: B31
  article-title: Resistance to therapy caused by intragenic deletion in BRCA2
  publication-title: Nature
  doi: 10.1038/nature06548
– volume: 21
  start-page: 819
  year: 2015
  ident: B38
  article-title: Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-2572
– volume: 5
  start-page: 387
  year: 2011
  ident: B14
  article-title: The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2011.07.001
– volume: 13
  start-page: 411
  year: 2012
  ident: B1
  article-title: New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm3376
– volume: 8
  start-page: 363
  year: 2008
  ident: B30
  article-title: Targeted therapy for cancer using PARP inhibitors
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2008.06.016
– volume: 13
  start-page: 433
  year: 2014
  ident: B20
  article-title: Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-13-0803
– volume: 19
  start-page: 5003
  year: 2013
  ident: B8
  article-title: BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-1391
– volume: 283
  start-page: 593
  year: 1980
  ident: B10
  article-title: (ADP-ribose)n participates in DNA excision repair
  publication-title: Nature
  doi: 10.1038/283593a0
– volume: 376
  start-page: 235
  year: 2010
  ident: B27
  article-title: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60892-6
– volume: 7
  start-page: 517
  year: 2006
  ident: B2
  article-title: Poly(ADP-ribose): novel functions for an old molecule
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm1963
– volume: 34
  start-page: 1217
  year: 2013
  ident: B6
  article-title: Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2013.01.006
– volume: 279
  start-page: 13659
  year: 2004
  ident: B16
  article-title: Identification and biochemical characterization of a Werner’s syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M311606200
– volume: 15
  start-page: R99
  year: 2005
  ident: B36
  article-title: DNA repair: the importance of phosphorylating histone H2AX
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2005.01.029
– volume: 27
  start-page: 2705
  year: 2009
  ident: B24
  article-title: Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.7681
– volume: 21
  start-page: 4257
  year: 2015
  ident: B5
  article-title: FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0887
– volume: 72
  start-page: 5588
  year: 2012
  ident: B19
  article-title: Trapping of PARP1 and PARP2 by clinical PARP Inhibitors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-2753
– volume: 10
  start-page: 293
  year: 2010
  ident: B7
  article-title: PARP inhibition: PARP1 and beyond
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2812
– year: 2015
  ident: B22
  article-title: Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP Inhibitors
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-15-0191-T
– volume: 273
  start-page: 5858
  year: 1998
  ident: B37
  article-title: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
  publication-title: J Biol Chem
  doi: 10.1074/jbc.273.10.5858
– volume: 362
  start-page: 1909
  year: 2010
  ident: B39
  article-title: Susceptibility pathways in Fanconi’s anemia and breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0809889
– reference: 23165508 - J Pathol. 2013 Feb;229(3):422-9
– reference: 24270682 - Clin Cancer Res. 2014 Feb 1;20(3):540-7
– reference: 25500058 - Clin Cancer Res. 2015 Feb 15;21(4):819-32
– reference: 23319766 - Cancer Discov. 2013 Jan;3(1):20-3
– reference: 21183466 - Nucleic Acids Res. 2011 Apr;39(8):3166-75
– reference: 9488723 - J Biol Chem. 1998 Mar 6;273(10):5858-68
– reference: 19047122 - Clin Cancer Res. 2008 Dec 1;14 (23 ):7917-23
– reference: 15829967 - Nature. 2005 Apr 14;434(7035):917-21
– reference: 25093514 - Breast Cancer Res. 2014 Jun 03;16(3):211
– reference: 20484397 - N Engl J Med. 2010 May 20;362(20):1909-19
– reference: 19553641 - N Engl J Med. 2009 Jul 9;361(2):123-34
– reference: 18264087 - Nature. 2008 Feb 28;451(7182):1116-20
– reference: 23118055 - Cancer Res. 2012 Nov 1;72 (21):5588-99
– reference: 24356813 - Mol Cancer Ther. 2014 Feb;13(2):433-43
– reference: 14734561 - J Biol Chem. 2004 Apr 2;279(14 ):13659-67
– reference: 23103855 - Cancer Discov. 2013 Jan;3(1):68-81
– reference: 20609468 - Lancet. 2010 Jul 24;376(9737):245-51
– reference: 18644251 - Curr Opin Pharmacol. 2008 Aug;8(4):363-9
– reference: 26217019 - Mol Cancer Res. 2015 Nov;13(11):1465-77
– reference: 24062981 - Front Oncol. 2013 Sep 11;3:228
– reference: 16912188 - Cancer Res. 2006 Aug 15;66(16):8109-15
– reference: 11016934 - J Biol Chem. 2000 Dec 29;275(52):40974-80
– reference: 15829966 - Nature. 2005 Apr 14;434(7035):913-7
– reference: 21300883 - Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
– reference: 26187614 - Clin Cancer Res. 2015 Oct 1;21(19):4257-61
– reference: 18980982 - Clin Cancer Res. 2008 Nov 1;14(21):6877-85
– reference: 22028822 - PLoS One. 2011;6(10):e26152
– reference: 15694301 - Curr Biol. 2005 Feb 8;15(3):R99-R102
– reference: 20200537 - Nat Rev Cancer. 2010 Apr;10 (4):293-301
– reference: 19364967 - J Clin Oncol. 2009 Jun 1;27(16):2705-11
– reference: 20609467 - Lancet. 2010 Jul 24;376(9737):235-44
– reference: 23881923 - Clin Cancer Res. 2013 Sep 15;19(18):5003-15
– reference: 22713970 - Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24
– reference: 17088286 - Nucleic Acids Res. 2006;34(21):6170-82
– reference: 10400681 - J Biol Chem. 1999 Jul 16;274(29):20521-8
– reference: 18264088 - Nature. 2008 Feb 28;451(7182):1111-5
– reference: 6243744 - Nature. 1980 Feb 7;283(5747):593-6
– reference: 21821475 - Mol Oncol. 2011 Aug;5(4):387-93
– reference: 24037533 - Oncogene. 2014 Jul 24;33(30):3894-907
– reference: 23370117 - Mol Aspects Med. 2013 Dec;34(6):1217-56
– reference: 16829982 - Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
– reference: 24259538 - J Med Genet. 2014 Feb;51(2):71-5
SSID ssj0000650103
Score 2.3052137
SecondaryResourceType review_article
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 222
SubjectTerms BRCA1
BRCA2
Cancer
Drug Resistance
Homologous Recombination
Oncology
PARP inhibitor
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7iQbyIb-uLCB68rM1u0u7m4EHFUgSlqIXeQp5YkK3Y9uC_dya7La0oXrwtm4QN32wyM3l8HyHnNtci00VIpDZ5IgLMg-D0eBI8F8w6lESKpy0e292-uB-0BgtSX3gmrKIHroBrCsNzkwfLkdyLeSaZyB2EKd6JLDgRmUDB5y0kU9Uc3EIBg4rLB7Iw2QyjEhkL07iEkmVLbiiy9f8UYn4_KbngejqbZKOOGel11dctsuLLbbL2UO-K75Cr52mUPfRjqktH7UwfZUxHgfaun3p0WL4OzRCFdeCRWrT0B62uXn3ukn7n7uW2m9SyCIkVLTkBQAFCgFIXzHsYk5nJICjTwrYLvLkjghTCcu1YFqxjrcJYyQMH5JyQWhcp3yOr5aj0B4RaB2UFc046SJFNIV1qisA8NLOQGLkGuZyhpGzNGY7SFW8KcgeEVSGsCmFVEdYGuZg3eK_oMn6veoOwz6shz3V8AdZXtfXVX9ZvkLOZ0RSMC9zs0KUfTccqRSJ-iOcy2SD7lRHnnwK8wCtzaJ0vmXepL8sl5fA1cm-LNrIR8cP_6PwRWUc40BOm4pisTj6m_gRCnIk5jX_zF_Ji-EE
  priority: 102
  providerName: Directory of Open Access Journals
Title Successes and Challenges of PARP Inhibitors in Cancer Therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/26528434
https://www.proquest.com/docview/1730025629
https://pubmed.ncbi.nlm.nih.gov/PMC4604313
https://doaj.org/article/4b37b7fc302140e09047d161ed42fd44
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA6ygvgi3h1Xlwg--NI1bc5Mm4dF1sF1FVYW3YF5C7nuDiypzgXWf-85aWd0ZARfCr2kbb7k5JyTpt_H2GtXG6hMEwtlbF1AxHEQnZ4sYpAgnCdJpLza4svodAKfp8PpbzmgHsDFztSO9KQm8-vDmx8_36HBH1HGif72bWwTkRGWeXakwvH4Nrqlmqz0rI_1u2F5SJoGJDZXSSgUyGlH9bPrHlteKpP574pA_15I-YdnOrnP7vUhJT_u-sADdiukh-zOWf_R_BE7-rbKqohhwU3yfLyWT1nwNvLz46_n_FO6mtkZ6e7wWeJj6ghzftHxDTxmk5MPF-PToldNKBwM1RLxRoQRadOIENBkK1thzGbAjRr6sQeiAnDSeFFF58WwsU7JKINQHpQxTSmfsL3UpvCMcefxXCO8Vx4zaNsoX9omioDFHOZNfsAO1yhp11OKk7LFtcbUgmDVBKsmWHWGdcDebAp879g0_n3pe4J9cxnRYOcD7fxS91alwcra1tFJYn4TWAcBtccYNnioogcYsFfrRtNoNvQtxKTQrha6JJ5-DPcqNWBPu0bcPArxQqctsXS91bxb77J9Js2uMjU3jIisSD7__3rus7u0Q-6whBdsbzlfhZcY5yztQZ4fwO3HaXmQ-_IvBRn6qQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successes+and+Challenges+of+PARP+Inhibitors+in+Cancer+Therapy&rft.jtitle=Frontiers+in+oncology&rft.au=Ricks%2C+Tiffany+K.&rft.au=Chiu%2C+Haw-Jyh&rft.au=Ison%2C+Gwynn&rft.au=Kim%2C+Geoffrey&rft.date=2015-10-14&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=5&rft_id=info:doi/10.3389%2Ffonc.2015.00222&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fonc_2015_00222
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon